Researchers report the impact of sparsentan vs irbesartan on proteinuria in patients with focal segmental glomerulosclerosis.

LightPath Technologies, Inc. ("LightPath," the "Company," "we," or "our"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: ...

SenesTech, Inc. , the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Controltm products, will report financial results for its ...

Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE)-- Ligand Pharmaceuticals ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics TVTX posted a profit for the first quarter on Monday. The company reported quarterly earnings of 5 cents ...

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over ...

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

(TVTX) on Monday reported a loss of $37.1 million in its first quarter.